Holen Sie sich die Stockscreener-App
3.87
0.26%
0.01
Handel nachbörslich:
3.91
0.04
+1.03%
Schlusskurs vom Vortag:
$3.86
Offen:
$3.88
24-Stunden-Volumen:
1.59M
Relative Volume:
1.69
Marktkapitalisierung:
$255.90M
Einnahmen:
$69.23M
Nettoeinkommen (Verlust:
$-33.10M
KGV:
-3.2797
EPS:
-1.18
Netto-Cashflow:
$-39.26M
1W Leistung:
-8.83%
1M Leistung:
+8.40%
6M Leistung:
-0.77%
1J Leistung:
+423.89%
1-Tages-Spanne:
$3.64
$3.98
1-Wochen-Bereich:
$3.64
$4.42
52-Wochen-Spanne:
$0.52
$5.92
Neuronetics Inc Stock (STIM) Company Profile
Firmenname
Neuronetics Inc
Sektor
Branche
Telefon
877-600-7555
Adresse
3222 PHOENIXVILLE PIKE, MALVERN, PA
Vergleichen Sie STIM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
STIM
Neuronetics Inc
|
3.87 | 255.24M | 69.23M | -33.10M | -39.26M | -1.18 |
|
ABT
Abbott Laboratories
|
129.40 | 228.03B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
102.50 | 152.09B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
378.95 | 143.98B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
92.91 | 117.98B | 33.54B | 4.69B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
77.68 | 45.17B | 5.69B | 1.41B | 577.90M | 6.95 |
Neuronetics Inc Stock (STIM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-08-13 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2021-10-13 | Herabstufung | BTIG Research | Buy → Neutral |
| 2021-10-13 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2021-01-22 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2020-02-06 | Eingeleitet | BTIG Research | Buy |
| 2018-07-24 | Eingeleitet | Canaccord Genuity | Buy |
Alle ansehen
Neuronetics Inc Aktie (STIM) Neueste Nachrichten
Neuronetics’ SWOT analysis: navigating growth in mental health tech stock By Investing.com - Investing.com South Africa
Neuronetics’ SWOT analysis: navigating growth in mental health tech stock - Investing.com
Neuronetics Stock Soars 7.25% on Institutional Investments - AInvest
Major Stakeholder Sells Millions in Neuronetics Stock! - TipRanks
How does Neuronetics Inc. compare to its peersFastest Growing Stock Radar - mustnews.co.kr
Neuronetics Study Shows Strong Antidepressant Results for Teens and Young Adults Using NeuroStar TMS - MSN
Can Neuronetics Inc. expand into new markets3x Potential Swing Trade Ideas - mustnews.co.kr
Neuronetics Issues Inducement Equity Awards to New Hires - MSN
Neuronetics Price Target Adjusted Down to $7, Analyst Maintains Buy Rating - AInvest
It's Down 25% But Neuronetics, Inc. (NASDAQ:STIM) Could Be Riskier Than It Looks - 富途牛牛
Neuronetics shares fall 3.42% intraday after granting inducement awards to new employees. - AInvest
Here's What Analysts Are Forecasting For Neuronetics, Inc. (NASDAQ:STIM) After Its Second-Quarter Results - simplywall.st
Neuronetics announces inducement grant - Medical Buyer
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Neuronetics Expands Leadership Team with 31,650 RSU Grants: Major Push in Neurohealth Tech - Stock Titan
Neuronetics (STIM): Canaccord Genuity Adjusts Price Target | STI - GuruFocus
Neuronetics: Canaccord Genuity maintains Buy, PT down to $7 from $8. - AInvest
Neuronetics adjusts 2025 gross margin guidance to 48%-50% as Greenbrook revenue mix rises - MSN
Neuronetics Takes A Leap In Mental Health Tech - Finimize
Neuronetics, Inc. (NASDAQ:STIM) Q2 2025 Earnings Call Transcript - Insider Monkey
Canaccord Genuity lowers Neuronetics stock price target on margin concerns By Investing.com - Investing.com Canada
Canaccord Genuity lowers Neuronetics stock price target on margin concerns - Investing.com
Neuronetics (STIM) Price Target Reduced by Canaccord Analyst - GuruFocus
Neuronetics Reports Q2 2025 Financial Results Surge - The Globe and Mail
Neuronetics: Q2 Earnings Snapshot - Greenwich Time
Neuronetics Inc (STIM) Q2 2025 Earnings Call Highlights: Record Revenue Growth Amid Strategic Shifts - GuruFocus
Neuronetics Inc (STIM) Q2 2025 Earnings Call Highlights: Record Revenue Growth Amid Strategic Shifts By GuruFocus - Investing.com Canada
Neuronetics 2025 Q2 Earnings Beats Expectations as Net Loss Narrows 54.5% - AInvest
Neuronetics Reports Revenue Growth Amid Greenbrook Acquisition - TipRanks
Neuronetics’ Earnings Call: Revenue Growth Amid Challenges - TipRanks
Neuronetics' 2025 Gross Margin Guidance: A Calculated Path to Profitability Amid Integration Challenges - AInvest
Neuronetics Q2 2025: Navigating Contradictions in Marketing Strategies and Revenue Expectations - AInvest
Earnings call transcript: Neuronetics Q2 2025 Misses EPS Forecast, Stock Drops - Investing.com
Neuronetics Q3 Revenue Forecast $37M-$39M, Close to Consensus Estimate of $38.22M - AInvest
Neuronetics 2025 Financial Forecast: Revenue Ranges from $149M to $155M, Gross Margin at 48%-50% - AInvest
Neuronetics Q3 Revenue Outlook: $37M-$39M vs. Consensus $38.22M - AInvest
Neuronetics (STIM) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Neuronetics Reports Second Quarter 2025 Financial and Operating Results | STIM Stock News - GuruFocus
Neuronetics Q2 2025 slides reveal strong revenue growth, path to profitability - Investing.com
Neuronetics Q2 Financial Results: $10.1 Million Loss ReportedNews and Statistics - IndexBox
Neuronetics earnings missed by $0.07, revenue topped estimates - Investing.com
Neuronetics' Q2 2025 Earnings: A Tale of Two Metrics – Revenue Growth vs. Persistent Losses - AInvest
Neuronetics, Inc. SEC 10-Q Report - TradingView
Neuronetics Reports Second Quarter 2025 Financial and Operating Results - The Globe and Mail
Healthcare firm Neuronetics Q2 revenue misses estimates - MarketScreener
Neuronetics Q2 revenue up 18% YoY to $38.1 mln. - AInvest
Neuronetics to Present at the Canaccord Genuity 45th Annual Growth Conference - The Manila Times
Neuronetics to Present at the Canaccord Genuity 45th Annual Grow - GuruFocus
Neuronetics, Inc. CEO Keith Sullivan to Present at Canaccord Genuity 45th Annual Growth Conference on August 12, 2025 - Quiver Quantitative
Neuronetics CEO Showcases Neurohealth Innovation at Major Growth Conference - Stock Titan
What To Expect From Neuronetics Inc (STIM) Q2 2025 Earnings - Yahoo Finance
Finanzdaten der Neuronetics Inc-Aktie (STIM)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.31%
1.36%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):